All News
Romo increased BMD across eGFR subgroups vs Pbo. Reduction in new vertebral fractures not affected by eGFR. https://t.co/HMkREcwoQj #ACR19 @RheumNow plenary#2730 #ACRbest https://t.co/9ojwhmmZxx
Dr. Rachel Tate uptoTate ( View Tweet)
Abstr# 2160: Myopenia is associated with risk of rotator cuff tearing in the elderly.
A great reminder to encourage exercise and building muscle mass to our patients. #ACR19 @RheumNow https://t.co/w5WrL6YcD7
Dr. Paul Sufka psufka ( View Tweet)
#ACR19 Poll: When treating PMR, how do you recognize when patients are having a relapse or flare while tapering steroids? @RheumNow
Dr. Paul Sufka psufka ( View Tweet)
Risk of progression of MGUS to myeloma is 1%/yr
#ACR19 @rheumnow 5T064 https://t.co/T0K0cNlW04
Dr Irwin Lim _connectedcare ( View Tweet)
@rheumnow #ACR19 ABS2353 Real-life observ cohort study demonstrates ACPA testing well adopted by US rheum (77.6% tested at Dx) but does not influence treatment choice (Rx w/bDMARD had similar distribution regardless of ACPA status) https://t.co/2V8VqHATJd
Olga Petryna DrPetryna ( View Tweet)
Abstr#2111-symptomatic coccidiomycosis more prevalent in pts using steroids with biologics. Nice retrospective study on this unmet need @RheumNow #ACR19
Cassandra Calabrese CCalabreseDO ( View Tweet)
@RheumNow #ACR19 abs2467 multicenter observational study analysis concludes sleep impairment in PsA is mainly mediated by subjective factors like anxiety and pain rather than inflammation https://t.co/q64dhsZILW
Olga Petryna DrPetryna ( View Tweet)
Nice study reminding us we need to do a better job of screening for chronic hepatitis B prior ritux (and ALL other forms of immunosuppressive) with HBsAg, HBcAb and HBsAb abstr#2100 @RheumNow #ACR19 @LCalabreseDO https://t.co/s7yogf6qC0
Cassandra Calabrese CCalabreseDO ( View Tweet)
COAST-X: IXE met ASAS 40 and all secondary endpoints in nr-axSpA vs PBO. https://t.co/V0QNfi33eA #ACR19 @RheumNow plenary#2729 #ACRbest https://t.co/VVkEfLpHzs
Dr. Rachel Tate uptoTate ( View Tweet)
Is there any data about the safety of 8000u of vitamin A daily? Just asking because I have no idea #ACR19 @RheumNow https://t.co/aLtCOgujdK
Philip Robinson philipcrobinson ( View Tweet)
Gout increases risk of fatal & non-fatal CVD events (in pop without previous CVD events)
No obvious protection from using Allopurinol
Population level study
#ACR19 @rheumnow Abst2732 https://t.co/yQu0PjkmIN
Dr Irwin Lim _connectedcare ( View Tweet)
Spending and price trending of bDMARDs. https://t.co/gB6xjvialr #ACR19 @RheumNow plenary#2731 https://t.co/YNpwYvTu1y
Dr. Rachel Tate uptoTate ( View Tweet)
Abstr# 2156: Something I had never heard of — Yao Syndrome.
This is an adult onset (mean 25.9yo at presentation) autoinflammatory syndrome associated with NOD2 mutations. #ACR19 @RheumNow https://t.co/J71t6uqrSx
Dr. Paul Sufka psufka ( View Tweet)
"We are all using biosimilars," said Dr. Bykerk, since TNFi approved in the 1990s have faced antigenic drift and changed over the years...
#ACR19 @RheumNow
Jonathan Hausmann MD hausmannMD ( View Tweet)
Abstract L06 shows the efficacy of Emapalumab, an IFN-γ mAb, when given to 9 systemic JIA pts who developed macrophage activation syndrome. Highly effective showing ability to lower steroid use #ACR19
#ACRBest https://t.co/OXTwpkyhlq
Dr. John Cush RheumNow ( View Tweet)
Yes, you read that right US$5,000,000,000 increase in biological DMARD spending #ACR19 @RheumNow Abs 2731 https://t.co/9Ew5II282Y
Philip Robinson philipcrobinson ( View Tweet)
#ACR19 Abst#2729 Plenary: Ixekizumab in NR-axSpA
Improved ASAS40 at wk16 (32% vs 12% PLBO, NNT~4). Wk52 open label f/u available, but hard to interpret
Remember this is a different population (non radiographic) than the upadacitinib trial that was also presented
@RheumNow https://t.co/tkYEfiqj7h
Mike Putman EBRheum ( View Tweet)
Abstr# 2612: Minocycline as an option for refractory calcinosis in scleroderma. 43% of patients reported some improvement. With few options available, this would be something to consider. #ACR19 @rheumnow https://t.co/yXvmUwaxzU
Dr. Paul Sufka psufka ( View Tweet)
We know ovarian insuff with cyclophosphamide is dose-related, but in SLE data from @EmoryUniversity @emoryhealthcare the absolute numerical diff between success & failure is tighter than I imagined. Other factors at play?
Also: time heals some wounds...
#ACR19 ABST2293 @RheumNow https://t.co/wI3S4ljjOJ
David Liew drdavidliew ( View Tweet)
Dr. Suzanne Li discusses juvenile localized scleroderma disease activity at #ACR19: jLS can cause severe damage. There is no universal activity feature for jLS so need to assess multiple features, such as
-Erythema
-Violaceous color
-Waxy white/yellow
#pedsrheum @RheumNow https://t.co/BpszRgHhyr
Dr. Erin Tree DrTinyTree ( View Tweet)